Carregant...

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Di Maio, Massimo, Daniele, Gennaro, Piccirillo, Maria Carmela, Giordano, Pasqualina, Signoriello, Giuseppe, Daniele, Bruno, Perrone, Francesco
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3712698/
https://ncbi.nlm.nih.gov/pubmed/24213324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers4020549
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!